Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Africa Development International
Street 1: D402/1 MTENDERE
Street 2: D402/1 MTENDERE
City: LUSAKA
Province: LUSAKA
Post Code: 10101
Country: Zambia
Phone: +26 0964451173
Organization Email: iafricadevelopment@yahoo.com
Web Site: http://sites.google.com/site/africadevinternationalzambia/
Other Online Presence:

Focal Point Contact Information

Salutation: Mr.
First Name: GEORGE
Last Name: MWANZA
Title: GLOBAL DIRECTOR
Email: mwanza.george@yahoo.com
Phone: +260 955605229

Alternate Focal Point Contact Information

Salutation: Ms.
First Name: SALOME
Last Name: SAKALA
Title: CEO
Email: sallysakala85@gmail.com
Phone: +260 954 637671

General Information

Board Constituency: Developing Country NGO
Is your organization legally registered in your country: Yes
If yes, please enter your registration number:
Organization Type - Primary: Non-Governmental Organization
Organization Type - Secondary: Other Non-Governmental Organization (NGO)
Organization Description:
MISSION

1. To facilitate sustainable integrated community development initiatives through community mobilization, capacity building and responses aimed at improved health, cultural, social and economic status of target communities.

Main focus of work: Communications, capacity building, monitoring and evaluation, Economic empowerment, Children/Women's rights, research and development through integrated development.

We are interested in Tuberculosis; TB is a health concern and issue which is one of the highly prevalent components in pediatrics HIV, HIV itself and is critical in treatment and adherence both in adults and Children.

We plan to scale up our efforts in mitigating the effects of TB in the communities. Currently, we continue to support adherence to treatment through the Medical Aid Project and communications as well as advocacy. We also plan to set up clinics or Rural Hospitals and/or partner with Government Hospitals in Rural areas in as far as we partner to implement both advocacy and adherence to TB Treatment. ADI has been providing medical aid to the pediatrics and Women (Mothers) who are co-infected with TB/HIV with adherence which includes nutrition, support/care and helping meet the gap with supplementary drugs procurement to enhance treatment and support. We further provided various activities in raising awareness on TB treatment and other co-infections with emphasis on discouraging traditional treatment combining with mainstream treatment in Hospitals.
 
Do you know about the UNHLM declaration:

Specializations / Areas of Work

Advocacy
Delivery of health services and care
Provision of drugs, diagnostics and commodities
Research and Development
Technical Assistance

Other Organization Information

Total number of staff in your organization: 11 - 25
Number of full-time staff who are directly involved with TB: 6 - 10
Number of part-time staff who are directly involved with TB: 6 - 10
Number of volunteers who are directly involved with TB: 11 - 25
 
How did you hear about the Stop TB Partnership: Other partners
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Network with other partners
 
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: No
Please tell us how your organization is contributing to your country's national TB control plan:
Through communications and advocacy, bridging the gaps in rural areas.
 

Geographical Reach

Which country is your headquarters located in: Zambia
Which countries do you do operate in:
(This includes countries you are conducting activities in)
Zambia

Contribution

Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

TB Care Delivery:
We plan to contribute immensely in mitigating TB impact on the Global Plan to Stop TB through research, media documentation and producing online and documentary/feature films on TB treatments, impacts and the best practices to combating TB. Furthermore, produce artistic and graphics communications in print through Magazines, social media etc for raising awareness to the General public and the Global Community. Our approach will include reaching out to the AFRICA Region with the aim of media and communications documentations for communications and development for positive change and enhanced care/support of TB treatment. We provide the communications services in prevention and treatment of TB and other co-infections. This is done collaboratively or purely as funded or fundraised by ADI to support the project.

Drug-Resistant TB:
We plan to discover more on the factors reading and relating to drug resistance after a period of time to certain beneficiaries. Our role will be both technical engagement through the facilities we will create and social or community mobilzation through campaigns and awareness in the communities and providing other media tools such as IEC materials we will produce under the Media Department.

TB-HIV:
Our role in duo treatment to TB-HIV is both on medical aid and treatment adherence support/care as well as nutritional advice and support too. In addition, we provide the advocacy on the best steps and practices in duo treatment and also, the need to avoid the mixture of traditional/mainstream drug administering to the beneficiaries for effective treatment.

Laboratory Strengthening:
continued Research through establishing well enhanced Laboratory facilities at our planned Community Hospitals in Rural and Peri-Urban areas with the aim of engaging directly in finding the practical workable solutions in the various challenges faced with TB treatment and complete elimination of the disease. The Laboratory which will aid the many activities on studies regards the disease and the co-infections correlating to treatment, adherence and eliminating the problem through enhanced problem definition resulting from the Laboratory studies and/or tests.

New Diagnostics:
Our approach will mainly be attached with media and communications regards providing the best effective communications tools to the beneficiaries on new diagnostics. This will include our research findings and collaboratively in communicating the best and good practices along with diagnostics in the communities. Both the scientific and best approved new diagnostics and adherence will be used by ADI Media to provide the communications platform so as to end and stop TB at all.

New TB Drugs:
Media and Communications approaches too; provide the advocacy and communications tools on administering treatment, care/support, adherence and other steps in mainstreaming new TB Drugs treatment in the communities.

New TB Vaccines:
We plan to collaborate with the Government and other stake holders in raising awareness on the new forms of vaccines available and provide the effective understanding as part of positive steps to eliminating TB in the communities.

Fundamental Research:
Our fundamental research will involve social and medical which will highlight greatly the social life, family, community and TB prevalence and treatment. through this approach, finding and/or exploring the new/hidden problems that contribute as factors to restraining effective treatment and drastic elimination of TB on the Continent.

Research:
The Community Hospitals which will feature laboratories will provide a platform for continued research in the TB treatment, problems and solutions consequently. As explained above, this will operate as a continued research point on the actual disease but will work jointly with the social or community researches which will build and enhance the efforts in countering TB.

Declaration

Declaration of interests:
The information provided is correct and there are no known conflict of interest for my Organization.

Application date: September 14, 2015
Last updated: April 24, 2024